Gyre Therapeutics GAAP EPS of -$0.02 misses by $0.09, revenue of $37.2M beats by $1.76M
Source: SeekingAlpha
2026-03-12 06:10:21 ET
More on Gyre Therapeutics
- Seeking Alpha’s Quant Rating on Gyre Therapeutics
- Historical earnings data for Gyre Therapeutics
- Financial information for Gyre Therapeutics
Read the full article on Seeking Alpha
For further details see:
Gyre Therapeutics GAAP EPS of -$0.02 misses by $0.09, revenue of $37.2M beats by $1.76M
Gyre Therapeutics Inc.
NASDAQ: GYRE
GYRE Trading
-1.67% G/L:
$8.24 Last:
48,693 Volume:
$8.10 Open:
GYRE Latest News
March 12, 2026 06:00:00 am
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 02, 2026 08:00:00 am
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
January 05, 2026 07:00:00 am
Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
November 07, 2025 06:00:00 am
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
GYRE Stock Data
$767,775,261
71,190,203
0.16%
17
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
